Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
NCT04136444 · UCB Biopharma S.P.R.L. · PHASE1 · terminated · last registry update 2021-07-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures” | – | Registry record, UCB Biopharma S.P.R.L. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-24Results posted on the registry: Mayo Clinic, Gabapentin + Benzodiazepines (NCT03012815)
- 2021-11-24Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Acamprosate + Lovastatin (NCT02998151)
- 2021-04-13Also stopped (withdrawn): Synchroneuron Inc., SNC-102 sustained release tablet (NCT02217007)
- 2021-04-13Also stopped (withdrawn): Synchroneuron Inc., SNC-102 + Placebo (NCT02064010)
- 2020-08-17Results posted on the registry: VA Salt Lake City Health Care System, Chlordiazepoxide + Gabapentin (NCT01573052)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision